Conference
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).
Authors
Parulekar W; Chapman JW; Aparicio S; Murray Y; Boyle FM; Di Leo A; Kaufman B; Levy C; Manikhas A; Martin M
Volume
29
Pagination
pp. tps108-tps108
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.tps108
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X